MetaVia is trading 7.5% down at $1.94 as investors lock in gains following a sharp rally driven by optimism surrounding its DA-1726 obesity drug trial milestone.
- The stock jumped approximately 11% on July 13, 2026, after the company reported that all active patients in Part 3 of its Phase 1 trial for DA-1726 successfully reached the highest planned doses.
- Today's downward move reflects a normalization of volatility and profit-taking after the recent catalyst-driven surge.